David Tougeron, Professor at Poitiers University Hospital, shared a post on LinkedIn:
“Very happy to share my last paper with Camille Evrard and many French digestive oncologists concerning the prognosis of third-line treatment in pancreatic cancer.
This tool determine survival in L3 and help treatment decision-making.
Try it!”
Title: Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
Journal: Oxford Academic
Authors: Camille Evrard, Antoine Pelras, Simon Rivet, Jean-Baptiste Bachet, Olivier Dubreuil, Anne-Laure Pointet, Julien Taieb, Widad Lahlou, Alix Portal, Céline Lepère, Thierry Lecomte, Romain Chautard, Nicolas Williet, Jean-Marc Phelip, Clélia Coutzac, Emilie Soularue, Lysiane Marthey, Raëf Abdallah, Anne Thirot Bidault, Pascal Artru, Jérome Desrame, Bertrand Le Roy, Marine Jary, Pascal Hammel, Isabelle Trouilloud, Nelson Lourenco, Vincent Hautefeuille, Laëtitia Dahan, Simon Pernot, Dominique Béchade, Astrid Pozet, Franck Bonnetain, Christophe Locher, Johann Dréanic, Romain Coriat, Bélinda Tchoundjeu, Yohann Foucher, David Tougeron
More posts featuring David Tougeron on OncoDaily.